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Abstract
Background: There is an increasing consensus in favour of integrated treatment of substance use
disorders and co-morbid conditions, such as depression or anxiety. However, up till now no
systematic reviews have been published.
Methods: Based on a systematic search of MedLine and PsychInfo, 9 trials of integrated treatment
for depression or anxiety plus substance use disorder were identified. Where possible, meta-
analyses were carried out, using random effects models.
Results: Meta-analyses were carried out for integrated treatment for depression and substance
use disorders on a number of outcomes. No meta-analysis could be carried out for integrated
treatment for anxiety and substance use disorders, due to multivariate reporting of outcomes in
original articles. Integrated treatment for depression and substance abuse produced significant
effects on percent days abstinent at follow-up. Differences in retention and symptoms were non-
significant, but favoured the experimental condition. For studies of integrated treatment for co-
morbid anxiety disorders and substance use disorders, no meta-analysis could be carried out.
Several studies of integrated treatment for anxiety and substance use disorders reported that
patients assigned to substance use treatment only fared better.
Conclusion: Psychotherapeutic treatment for co-morbid depression and substance use disorders
is a promising approach, but is not sufficiently empirically supported at this point.
Psychotherapeutic treatment for co-morbid anxiety and substance use disorders is not empirically
supported. There is a need for more trials to replicate the findings from studies of integrated
treatment for depression and substance use disorders, and for the development of new treatment
options for co-morbid anxiety and substance use disorders.
Background
The prevalence of other psychiatric diagnoses among
those with substance-related disorders is notable [1,2].
Around 25% of people in the community in the United
States with alcohol dependence and around 50% of peo-
ple with drug dependence have co-morbid depression [2].
Anxiety disorders can be diagnosed in around 25% of
alcohol dependent people and 43% of drug dependent
people [2]. Jané-Llopis and Matytsina reviewed surveys
from around the world, and found that studies have
shown converging evidence for high co-morbidity, recom-
mending that integrated services should be available for
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patients with co-morbid psychiatric conditions and sub-
stance use disorders [1].
Co-morbid psychiatric diagnoses accompanying alcohol
addiction, such as severe cases of anxiety or depression,
may have a negative impact on quality of life, and on
functioning and ability to respond to treatment [3,4].
However, little is known about how to effectively treat
these common co-morbidities in substance abusers. Tiet
and Mausbach reviewed the literature on integrated treat-
ment, and found that few studies have assessed the effec-
tiveness of integrated treatments for substance use
disorders with co-morbid disorders [5].
There is currently some evidence that medications can be
effective for co-morbid depression and substance use dis-
orders [6,7].
Among non-substance using patients with anxiety and
depression, there is a substantial amount of evidence sup-
porting the efficacy of psychotherapies. For instance, there
is robust evidence that cognitive-behavioural therapies
can be effective for anxiety disorders [8], and short-term
psychodynamic therapy as well as cognitive-behavioural
therapy has been shown to be effective for mood disorders
such as depression and dysthymia [9].
There is less evidence that non-somatic treatments such as
psychotherapy or behaviour therapy is effective for co-
morbid depression and substance use disorders (SUD),
and there are no empirically supported treatments for co-
morbid anxiety and substance use disorders.
In principle, psychotherapies could be useful in at least
three ways: psychotherapies could alleviate the symptoms
of depression or anxiety, thereby improving the patients'
quality of life. They could help patients understand their
co-morbidity better, so that the patients were able to
understand the link between psychiatric symptoms and
relapse, thereby enhancing better coping with urges and
cravings, and thereby directly reduce substance use inde-
pendently of effects on depression and anxiety. And
finally, they could improve both. In this review, both out-
comes in terms of substance use and in terms of symp-
toms are considered. For any review that combines data, it
is a great challenge when the measures representing
related outcomes vary. The choice of the reviewer may be
to exclude a substantial proportion of the literature in
order to obtain a homogeneous outcome measure, or to
combine various outcomes. Both decisions lead to advan-
tages and disadvantages for the outcomes of the review.
Excluding a large number of studies may mean that clini-
cally important information is lost. Combining very dif-
ferent measures may result in the inclusion of measures
that lack validity and reliability, thereby leading to the
wrong conclusions. However, what is available to the
reviewer is not known until the literature search has been
conducted. For this reason, there is a degree of compro-
mise involved.
Methods
A comprehensive search of Medline and PsycINFO was
carried out, combining terms reflecting depression 1.
("mood" or "depression" or "depressive"), or 2. ("anxi-
ety") with terms reflecting substance use disorders ("sub-
stance abuse" or "substance dependence" or "cocaine" or
"heroin" or "cannabis" or "alcohol"), and terms reflecting
randomized controlled designs ("randomized" or "con-
trol group") and terms reflecting non-somatic interven-
tions ("behavioral therapy" or "psychotherapy" or
"psychosocial intervention"). Additional searchers using
the same search-words were carried out on the Cochrane
register of clinical trials and CINAHL. References of
included studies were hand-searched, and registers of clin-
ical trials were searched (Clinical Trials, Current Control-
led Trials, controlled-trials.com, National Health Service
Research and Development Health Technology Assess-
ment Programme (HTA), National Institute of Health,
ClinicalTrials.gov). Additional searches were also carried
out using "MDMA" as a keyword, but no further studies
were identified.
Inclusion criteria
All patients in the sample had substance use disorders.
Only adults included in the study. Patients in the sample
had been selected for depressive or anxiety symptoms or a
diagnosis of depression or anxiety. The study compared
an integrated non-somatic treatment for both substance
use disorders and depression or anxiety with a treatment
programme solely focusing on the substance use disorder.
The study employed a randomized controlled design.
Data at post-treatment and/or at follow-up on retention,
psychiatric symptoms or substance use outcomes. Only
published studies were included. No language restrictions
were used.
Exclusion criteria
Interventions with a mixture of somatic and non-somatic
treatments (i.e. where patients were randomized to a com-
bination of pharmacotherapy and psychotherapy vs. pla-
cebo). Note that studies where subjects who were
randomized to non-somatic treatments were included,
even if they were allowed to receive pharmacotherapy dur-
ing the trial. Studies were excluded only if the experimen-
tal condition differed from the control condition in terms
of medication status, or if schizophrenia spectrum disor-
der or personality disorder required for inclusion into
study.BMC Psychiatry 2009, 9:6 http://www.biomedcentral.com/1471-244X/9/6
Page 3 of 8
(page number not for citation purposes)
Data extraction and analysis
Data were extracted by the author alone. In the present
review, data were analysed using the following outcome
measures:
Substance use
As all studies that reported substance use outcomes
reported percent days abstinent (PDA), and as PDA is a
widely used and well-validated measure of substance use
severity, this measure was chosen as the indicator of sub-
stance use, and the Weighted Mean Difference (WMD)
between the control and experiment group was estimated
at the follow-up point most commonly reported (6
months).
Interviewer-rated symptoms
As all studies that reported interviewer-rated symptoms
used the Hamilton Rating Scale for Depression (HRSD),
and as the HRSD is a widely used and well-validated
measure of depression, this measure was chosen as the
outcome measure for interviewer-rated symptoms, and
the WMD between the control and experiment group was
estimated at the follow-up points.
Completion of treatment
From studies that reported differential retention in treat-
ment, the proportion of patients who completed the
experimental and control treatment was extracted.
Meta-analyses were conducted using RevMan 4.1 from
Cochrane Collaboration, and are presented in RevMan
forest plots. For Hamilton Rating Scales and Percent Days
Abstinent, Weighted Mean Differences [WMD] were cal-
culated. For all self-report measures of anxiety and all
other substance use outcomes combined, Standardized
Mean Differences [SMD] were calculated. For retention in
treatment, Odds Ratio [OR] was calculated. For all meta-
analyses, random effects models were used, as the studies
were heterogeneous both with regard to interventions and
types of patients. For all outcomes, the I2 statistic was
reported. The I2 represents the degree of heterogeneity and
can range from 0 to 1. The group that first presented the I2
statistic tentatively suggested that values of 25%, 50%,
and 75% represent low, moderate, and high heterogeneity
[10]. The I2 statistic represents the extent of heterogeneity,
rather than the statistical significance of heterogeneity.
Results
In Medline, this search resulted in 118 hits, and in Psy-
cINFO, it resulted in 155 hits. Reviews and titles suggest-
ing non-somatic treatments for co-morbid anxiety or
depression and substance use disorders were retrieved.
Reference lists of reviews and published studies were
examined, and studies reporting randomized controlled
trials were included. Searches of Cochrane register of clin-
ical trials and CINAHL did not provide additional studies.
Of these reported articles, ten randomized controlled tri-
als that satisfied the inclusion criteria were identified. Five
studies were identified that compared integrated treat-
ments for mood disorders and substance use disorders
with treatment only for substance use disorders, and five
studies that compared integrated treatment for anxiety
and substance use disorders with treatments for only sub-
stance use disorders.
Description of studies
Five randomised studies provided manual-guided treat-
ment for co-morbid depression or depressive symptoms
and substance use disorders [11-15]. Details of the studies
are provided in table 1 and 2.
The studies are small, with only 223 patients randomized
in total. One study used a rarely studied model called self-
examination therapy [11], two studies assigned patients to
cognitive-behavioural therapy or control [12,13], one
study assigned patients to a mainly behavioural interven-
tion [14], and one study assigned patients to interpersonal
psychotherapy vs. placebo [15].
Bowman and colleagues compared Self-examination ther-
apy with an attention placebo treatment for co-morbid
depression in patients with substance use disorders and
co-morbid depressive symptoms during inpatient treat-
ment [11]. In Self-examination therapy, "people are given
a booklet which uses a flow chart format and encourages
them to: (a) determine what matters to them, (b) think
less negatively about things that do not matter to them,
(c) invest their energy in things that are important to
them, and (d) accept situations they cannot change."
[[11], p. 130]. The authors did not report the number of
patients receiving medication.
Richard A. Brown and colleagues compared cognitive
therapy for depression with relaxation training as part of
a partial hospitalization program for alcohol depend-
ence [12]. The cognitive therapy condition, called the
"Coping with depression course", incorporated training
in depression-relevant skills such as mood monitoring,
pleasant activities, constructive thinking, and social
skills. [12]. Nearly half the patients (45%) received med-
ication.
Sandra A. Brown and colleagues compared integrated cog-
nitive therapy for depression and substance dependence
with Twelve Steps Facilitating therapy [13]. Patients were
recruited from a dual diagnosis clinic, and all patients
were diagnosed using a structured interview (the CIDI).BMC Psychiatry 2009, 9:6 http://www.biomedcentral.com/1471-244X/9/6
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Almost all (97%) patients received pharmacotherapy for
depression.
Daughters and colleagues provided a brief behavioural
activation therapy for patients with co-morbid depression
and illicit drug use. The program was called Life Enhance-
ment Treatment for Substance Use (LETS Act) [14]. The
treatment ran over 6 sessions, plus optional maintenance
sessions, and involved among other things defining life
goals, identifying relevant activities, self-monitoring and
progressive muscle relaxation.
Finally, Markowitz and colleagues allocated patients with
dysthymia and alcohol problems to interpersonal psycho-
therapy or supportive psychotherapy.
Meta-analyses
In terms of outcomes measured as depressive symptoms,
the results of the meta-analyses are shown in figures 1, 2,
3 and 4.
Four studies reported Hamilton Rating Scale for Depres-
sion outcomes at post-treatment [HRSD] [12-15]. The
combined effect was -4.6 points on the HRSD for experi-
mental condition compared with control (95% confi-
dence interval -7.4 to 1.7). There was significant and
moderately high heterogeneity in the outcome (I2 = 0.61,
p = 0.05).
Four studies reported self-report questionnaire outcomes
for depression [11,12,14,15]. The combined effect was d
= -0.58 (95% confidence interval -1.10 to -0.06). Hetero-
geneity was not significant and low to moderate (I2 = 0.46,
p = 0.14).
Three studies reported percent days abstinent after treat-
ment at follow-up [12,13,15]. The combined effect was a
reduction of 14.13 in percent days abstinent for the exper-
imental condition (95% confidence interval 2.14 to
26.12, p = 0.02). Heterogeneity was low (I2 = 0.17, p =
0.30).
Three studies reported drop-out from treatment
[11,13,14]. The pooled effect size was 0.67 (95% confi-
dence interval 0.31 to 1.49, p = 0.33).
Table 1: Characteristics of studies integrating treatments for depression and substance use disorders





Bowman et al., 1996 [11] Male substance 
abusers in an inpatient 
treatment program.
Not reported Elevated symptoms 









Brown et al., 1997 [13] Alcohol dependent 
patients recruited 
from a day partial 
hospital program





HRSD and BDI post-
treatment, Percent 
Days Abstinence at 
follow-up
Brown et al., 2006 [12] Alcohol dependent 
patients recruited 
from a dual diagnosis 
program




versus Twelve Steps 
Facilitating therapy
HRSD and Percent 
Days Abstinence post-
treatment and at 
follow-up, and 
retention
Daughters et al., 2008 [14] Inpatients dependent 
on various substances
10% Elevated symptoms 
(BDI)
LETs act versus 
treatment as usual
HRSD and BDI post-
treatment and 
retention
Markowitz et al, 2008 [15] Patients recruited 
through flyers and 
advertising
0% SCID Dysthymia Interpersonal 
therapy versus brief 
supportive 
psychotherapy
HRSD, BDI, and PDA
Table 2: Number randomized and followed up in included studies
Number randomized (experimental/control) Number followed (experimental/control)
Bowman et al., 1996 [11] 14/14 11/11
Brown et al., 1997 [13] 19/16 18/15
Brown et al., 2006 [12] 48/42 28/18
Daughters et al., 2008 [14] 22/22 20/19
Markowitz et al, 2008 [15] 14/12 8/10BMC Psychiatry 2009, 9:6 http://www.biomedcentral.com/1471-244X/9/6
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Integrated treatment for anxiety and substance use 
disorders versus treatment for substance use disorders 
alone
Five trials have been published of the treatment of co-
morbid anxiety and substance dependence, three target-
ing alcohol dependence [16-18], and two targeting mixed
populations of drug and alcohol abusers [19,20]. All stud-
ies have assigned patients to variants of cognitive-behav-
ioural interventions.
As two of the five trials reported only multivariate out-
comes, no meta-analysis was conducted [16,17]. Instead,
the findings will be reviewed in the following.
Bowen and colleagues randomly assigned inpatients to
either alcoholism treatment alone or to alcoholism treat-
ment plus cognitive-behavioural therapy for co-morbid
anxiety [16]. The treatment group received 12 hours of
CBT for panic disorder in addition to the regular 4-week
alcoholism treatment program, and the control group
received only the regular program. No treatment group
effects were observed on social anxiety or alcohol drinking
indices.
Fals-Stewart and Schafer assigned patients in a therapeutic
community with obsessive-compulsive disorder (OCD)
to a control group, progressive muscle relaxation, or indi-
vidual behaviour therapy for OCD [19]. Patients assigned
to OCD treatment had lower NIMH Obsessive-compul-
sive scale scores at post-treatment and 12 months follow-
up than the patients in the other groups, and a higher pro-
portion of these patients remained abstinent (11 of 19, vs.
11 of 38).
Randall and colleagues randomly assigned patients to
alcoholism treatment alone, or to alcoholism treatment
plus CBT for social anxiety disorder [17]. The findings
indicated that anxiety outcomes were similar, but that
alcoholism treatment alone was superior in terms of
drinking outcomes. The treatment sessions were longer
for the integrated treatment (90 minutes versus 60 min-
utes).
Schadé and colleagues randomly assigned patients to
either treatment for alcoholism alone or treatment for
anxiety plus alcoholism in weekly 60-minutes therapy ses-
sions [18]. No significant differences were found for
Hamilton Rating Scale for Depression outcomes Figure 1
Hamilton Rating Scale for Depression outcomes. Notes: SD: Standard deviation. Z is the Zeta statistic for significance of 
pooled effect size. I2 is the degree of heterogeneity of the effect size. CI: Confidence interval.
Self-reported depressive symptoms outcome (SCL-90 or BDI) Figure 2
Self-reported depressive symptoms outcome (SCL-90 or BDI). Notes: SD: Standard deviation. Z is the Zeta statistic 
for significance of pooled effect size. I2 is the degree of heterogeneity of the effect size. CI: Confidence interval.BMC Psychiatry 2009, 9:6 http://www.biomedcentral.com/1471-244X/9/6
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drinking outcomes, but anxiety reductions were signifi-
cantly higher for the integrated treatment group.
Hien and colleagues assigned patients to either treatment
as usual in the community, cognitive relapse prevention
or a specialized PTSD program, "Seeking Safety", a short-
term, manualized cognitive-behavioural treatment that
simultaneously addresses trauma and substance abuse.
While both intervention groups fared better than the con-
trol group, the results did not favour the Seeking Safety
intervention over relapse prevention, with overall slightly
better outcomes with relapse prevention [20].
Discussion
The present meta-analysis showed that integrated psycho-
social treatment for depression and substance use disor-
ders is a promising approach for patients with this co-
morbidity. The analyses favoured integrated treatment
over single-focus treatments for percent days abstinent,
depressive symptoms and retention in treatment,
although percent days abstinent was the only statistically
significant finding, and substantial heterogeneity was
observed in several outcomes.
The meta-analyses conducted for integrated non-somatic
treatment for co-morbid substance use disorders and
depression indicated that while in general, outcomes
favoured an integrated treatment, the difference was sta-
tistically significant for only one out of four selected out-
comes (percent days abstinent at follow-up). Thus, while
integrated treatment for depression and substance use dis-
orders are promising, additional studies are needed. Also,
given the small sample sizes in the studies, a risk exists
that negative studies of similar have gone unpublished.
The number of studies that could be included was not suf-
ficient to conduct more formal analyses of publication
bias.
Quality and variability of published studies
A substantial improvement in the reporting of clinical tri-
als is expected with the endorsement of the CONSORT
statement [21]. The CONSORT statement involves the
reporting of data, including the description of study,
methods and outcome. None of the included studies
adhered to the CONSORT statement [21], although one
recent study did provide the flowchart as recommended in
the CONSORT statement [14]. In general, however, the
Percent days abstinent outcomes Figure 3
Percent days abstinent outcomes. Notes: SD: Standard deviation. Z is the Zeta statistic for significance of pooled effect 
size. I2 is the degree of heterogeneity of the effect size. CI: Confidence interval.
Drop-out from treatment outcomes Figure 4
Drop-out from treatment outcomes. Notes: SD: Standard deviation. Z is the Zeta statistic for significance of pooled 
effect size. I2 is the degree of heterogeneity of the effect size. CI: Confidence interval.BMC Psychiatry 2009, 9:6 http://www.biomedcentral.com/1471-244X/9/6
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reporting of data was adequate and transparent, and out-
comes were measured with adequately validated instru-
ments. The main limitation of the studies was the small
sample size of all the studies. A serious threat to internal
validity of one study in particular was the high attrition of
the study by Sandra Brown and colleagues, where less
than half the control subjects were included in the follow-
up analyses [13]. This is particularly problematic, as this
study is also the single largest trial among all the studies
of interventions for co-morbid depressive disorders.
Another key issue concerning the quality of the studies is
the criteria for depressive disorders. As can be seen from
table 1, the diagnostic criteria vary from elevated scores on
self-report questionnaires to CIDI and SCID diagnoses.
The studies also varied substantially in terms of setting,
types of substances used, and type of interventions. This
variability strongly suggests that psychotherapeutic treat-
ments should be considered promising rather than sup-
ported for co-morbid substance use disorders and
depression.
For anxiety disorders, no meta-analysis could be con-
ducted. However, based on this narrative review there is
currently little evidence that offering non-somatic treat-
ment for co-morbid anxiety disorders to patients with
substance use disorders will yield any significant benefit;
several studies report that outcomes for integrated treat-
ment produced worse results that treatment that focused
on substance use disorders alone [17,20]. One possible
exception is treatment for co-morbid Obsessive-Compul-
sive Disorder [19], but this is based on a single, very small
trial.
At present, there is a need for more and larger trials in
order to study the effectiveness of psychological interven-
tions for co-morbid depression and substance use disor-
ders, and a need to develop new treatment options for co-
morbid anxiety and substance use disorders. Some studies
are ongoing (Treatment of co-morbid Depression and
Substance Abuse in Young People, NCT00232284; Group
Therapy for Women Prisoners With co-morbid Substance
Use and Depression, NCT00606996; Outpatient Adoles-
cent Treatment for co-morbid Substance Use and Internal-
izing Disorders, NCT00438685).
Conclusion
Psychotherapeutic treatment for co-morbid depression
and substance use disorders is a promising approach, it is
not sufficiently empirically supported at this point. Psy-
chotherapeutic treatment for co-morbid anxiety and sub-
stance use disorders is not empirically supported. There is
a need for more trials to replicate the findings from stud-
ies of integrated treatment for depression and substance
use disorders, and for the development of new treatment
options for co-morbid anxiety and substance use disor-
ders.
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